PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Saladax Biomedical, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Saladax Biomedical, Inc. Announces Presentation of CEPAC - TDM Study of Paclitaxel in Non-Small Cell Lung Cancer At 2015 ASCO Meeting - Large Study Confirms the Benefit to Patients of Advanced Dosing Method for Chemotherapy - Saladax.com
Saladax Biomedical, Inc. Announces Presentation of CEPAC - TDM Study of Paclitaxel in Non-Small Cell Lung Cancer At 2015 ASCO Meeting

 

NewswireToday - /newswire/ - Bethlehem, PA, United States, 2015/06/05 - Large Study Confirms the Benefit to Patients of Advanced Dosing Method for Chemotherapy - Saladax.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Saladax Biomedical, Inc. presented results today from the largest, randomized, prospective dose adjustment-therapeutic drug monitoring (TDM) trial ever conducted in oncology: evaluating 304 patients over six years (abstract # 8051). The CEPAC-TDM phase III study in advanced Non-Small Cell Lung Cancer (NSCLC) patients (ClinicalTrials.gov Identifier NCT01326767) compared two arms one with dose optimization [pharmacokinetically (PK)-guided] to one with standard dosing. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015 taking place in Chicago, Illinois. The presentation is available on the Saladax website.

CEPAC-TDM was a study of paclitaxel (PTX) dosing in NSCLC patients receiving PTX in combination with carboplatin on a 3-weekly schedule. Standard dosing of chemotherapy does not account for the many differences between patients which make drug exposure highly variable, and variability of exposure can lead to severe toxicity and/or shorter survival.

Patients with advanced NSCLC receiving PTX/carboplatin chemotherapy were enrolled at nine German and one Swiss institution. In the PK-Guided Arm the majority of patients saw a significant eduction in the dose with fewer toxic side effects and the same survival as the Standard Arm. This well controlled, randomized study showed that using PK-Guided dosing with 3-weekly PTX in NSCLC patients results in a clinically significant reduction of both neutropenia and neuropathy compared to Standard dosing. The reduction in neuropathy is particularly important because it is impossible to treat or prevent this often debilitating side effect. The lower average PTX doses only reduced toxicity and did not reduce efficacy, confirming the value of PK-guided dosing with chemotherapy patients.

At the same conference, interim study results from a similar randomized study in NSCLC (ClinicalTrials.gov Identifier NCT02058433) reported from Shanghai Pulmonary Hospital in China presented very consistent trends further demonstrating the value of PK-Guided dosing (abstract # 8052).

About Saladax Biomedical, Inc.

Saladax Biomedical (saladax.com) is a leader in the development high-value diagnostic services and products. Products that deliver actionable data to help physicians select and optimize the use of current and new pharmaceutical products to improve health and positively impact the economics of care: diagnostics that make a difference. Headquartered in Bethlehem, Pennsylvania, Saladax was founded in 2004 and is ISO 13485:2003 certified.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Saladax Biomedical, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Saladax Biomedical, Inc. Announces Presentation of CEPAC - TDM Study of Paclitaxel in Non-Small Cell Lung Cancer At 2015 ASCO Meeting

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Salvatore Salamone - Saladax.com 
610-419-6731 ssalamone[.]saladax.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Saladax Biomedical, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Saladax Biomedical, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)